Results 1 to 10 of about 358,343 (288)

The Effect of the Timing of Dexamethasone Administration in Patients with COVID-19 Pneumonia [PDF]

Tuberculosis and Respiratory Diseases, 2021
Background Despite the proven benefits of dexamethasone in hospitalized coronavirus disease 2019 (COVID-19) patients, the optimum time for the administration of dexamethasone is unknown.
Hyun Woo Lee, Jimyung Park, Jung-Kyu Lee, Tae Yeon Park, Eun Young Heo   +4 more
doaj   +1 more source

Acute Activation of Metabolic Syndrome Components in Pediatric Acute Lymphoblastic Leukemia Patients Treated with Dexamethasone. [PDF]

PLoS ONE, 2016
Although dexamethasone is highly effective in the treatment of pediatric acute lymphoblastic leukemia (ALL), it can cause serious metabolic side effects.
Lidewij T Warris, Erica L T van den Akker, Marc B Bierings, Cor van den Bos, Christian M Zwaan, Sebastiaan D T Sassen, Wim J E Tissing, Margreet A Veening, Rob Pieters, Marry M van den Heuvel-Eibrink   +9 more
doaj   +1 more source

Dexamethasone pretreatment impairs the thymidylate synthase inhibition mediated flare in thymidine salvage pathway activity in non-small cell lung cancer. [PDF]

PLoS ONE, 2018
INTRODUCTION:Successful inhibition of thymidylate synthase (TS) by pemetrexed, a TS inhibitor, results in a reproducible transient burst or "flare" in thymidine salvage pathway activity at 2 hrs.
Xiao Chen, Yizeng Yang, Sharyn I Katz
doaj   +1 more source

Efficiency of a dexamethasone nanosuspension as an intratympanic injection for acute hearing loss

Drug Delivery, 2022
Dexamethasone sodium phosphate (Dex-SP) is the most commonly used drug administered via intratympanic injection for the treatment of acute hearing loss, but its penetration efficiency into the inner ear is very low.
So-Young Jung, Subin Kim, Zion Kang, Soonmin Kwon, Juhye Lee, Joo Won Park, Kab Sig Kim, Dong-Kee Kim   +7 more
doaj   +1 more source

Factors associated with the response to postnatal dexamethasone use in very low birthweight infants: a nationwide cohort study

BMJ Paediatrics Open, 2023
Background Dexamethasone is widely used as a systemic corticosteroid to treat and prevent bronchopulmonary dysplasia (BPD) in preterm infants. We evaluated the current epidemiology of dexamethasone use to prevent BPD and analyse the factors associated ...
Soon Min Lee, Min Soo Park, So Jin Yoon, In Gyu Song, Seung Hwan Baek, Jeong Eun Shin, Jungho Han, Joonsik Park, Su Min Lee, Sungbo Shim, Ho Seon Eun, Joohee Lim, Wook Chang   +12 more
doaj   +1 more source

The effect of dilution with glucose and prolonged injection time on dexamethasone-induced perineal irritation – A randomized controlled trial

Open Medicine, 2022
Dexamethasone can be used to prevent nausea and vomiting after surgery, but there is concern that it may induced perineal irritation. The aim of this study was to investigate the attenuation effect of dilution and slow injection on dexamethasone-induced ...
Zhang Yonghai, Liang Hong, Huang Liwei, Zheng Junwei, Chen Yi, Li Bin, Yang Fan, Yu Jingfang, Ma Hanxiang   +8 more
doaj   +1 more source

The Effect of Dexamethasone Treatment on COVID-19 Prognosis in Cancer Patients

Vaccines, 2022
Background: Dexamethasone is used to treat cancer, relieve chemotherapy-induced nausea and vomiting, enhance cancer patients’ appetites, and treat COVID-19 patients. There is little evidence of the impact of a dexamethasone treatment plan on the severity
Lina Souan, Zienab Al-Khairy, Maysaa’ Adnan Al-Binni, Abdelkader Battah, Maher A. Sughayer   +4 more
doaj   +1 more source

The Efficacy of High-Dose Dexamethasone vs. Other Treatments for Newly Diagnosed Immune Thrombocytopenia: A Meta-Analysis

Frontiers in Medicine, 2021
Objective: To compare the therapeutic efficacies of high dose dexamethasone, prednisone and rituximab in combination with dexamethasone for newly diagnosed ITP (Immune Thrombocytopenia, ITP) patients.Methods and results: Relevant publications for this ...
Qirong Xiao, Qirong Xiao, Bicun Lin, Bicun Lin, Hanyu Wang, Weiwu Zhan, Weiwu Zhan, Ping Chen, Ping Chen   +8 more
doaj   +1 more source

Dexamethasone Improves Cardiovascular Outcomes in Critically Ill COVID-19, a Real World Scenario Multicenter Analysis

Frontiers in Medicine, 2022
BackgroundSevere COVID-19 pneumonia requiring intensive care treatment remains a clinical challenge to date. Dexamethasone was reported as a promising treatment option, leading to a reduction of mortality rates in severe COVID-19 disease.
Peter Jirak, Vincent van Almsick, Dimitrios Dimitroulis, Moritz Mirna, Clemens Seelmaier, Zornitsa Shomanova, Bernhard Wernly, Bernhard Wernly, Bernhard Wernly, Dilvin Semo, Daniel Dankl, Magdalena Mahringer, Michael Lichtenauer, Uta C. Hoppe, Holger Reinecke, Rudin Pistulli, Robert Larbig, Robert Larbig, Lukas J. Motloch   +18 more
doaj   +1 more source

Dexamethasone bovine pharmacokinetics [PDF]

European Journal of Drug Metabolism and Pharmacokinetics, 1991
Dexamethasone phosphate (DXM-PHO) is an ester which is quickly hydrolysed by the bovine and the dexamethasone (DXM) plasma half-life was 5.16 h. It has been demonstrated that 54 h after DXM-PHO injection, DXM concentrations were lower than 0.1 mg/ml.
Gaignage, Ph, Lognay, Georges C., Bosson, Danièle, Vertongen, D., Dreze, Ph, Marlier, Michel, Severin, Michel   +6 more
openaire   +2 more sources